{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:06:19Z","timestamp":1791414379290,"version":"4.3.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deanship of Research and Graduate Studies at Yarmouk University","award":["25\/2023"],"award-info":[{"award-number":["25\/2023"]}]},{"name":"Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study investigates the effect of myricetin as a therapeutic for benign prostatic hyperplasia (BPH) disease using a testosterone-induced BPH animal model. Forty adult male rats were randomly divided into four groups as follows: control group, BPH group that was injected with testosterone subcutaneously (3\u00a0mg\/kg body weight\/day), BPH\u2009+\u2009myricetin group, which received myricetin (50\u00a0mg\/kg) subcutaneously every day with the BPH induction, and BPH\u2009+\u2009finasteride group, which administered finasteride orally with the BPH induction at a daily dose of 5\u00a0mg\/kg. After 28\u00a0days, blood and prostate tissue samples were collected for analysis. Compared to the control group, treatment with myricetin improved the pathohistological signs of BPH and enhanced the antioxidant and anti-inflammatory capacity of the prostatic tissue, as evidenced by its ability to enhance the total antioxidant capacity (TAC) levels and reduce malondialdehyde (MDA) levels, decrease the levels of the inflammatory biomarkers tumor necrosis factor alpha (TNF-\u03b1) and interleukin-1 beta (IL1-\u03b2) levels, and reduce serum dihydrotestosterone (DHT) levels. In addition, myricetin treatment showed beneficial effects through its ability to reduce the prostatic mRNA expression levels of the anti-apoptotic protein Bcl2, the\n                    <jats:italic>5-\u03b1 reductase<\/jats:italic>\n                    enzyme, and the androgen receptor (\n                    <jats:italic>AR<\/jats:italic>\n                    ), while simultaneously increasing the prostatic mRNA expression levels of the pro-apoptotic protein\n                    <jats:italic>Bax<\/jats:italic>\n                    . Myricetin treatment also exhibited anti-proliferative and anti-angiogenic effects, as evidenced by the reduced prostatic proliferating cell nuclear antigen (PCNA) and vascular endothelial growth factor-A (\n                    <jats:italic>VEGF-A<\/jats:italic>\n                    ) mRNA expression levels. In summary, myricetin displays potential as a BPH therapy by diminishing inflammation and oxidative stress, hindering\n                    <jats:italic>5-\u03b1 reductase<\/jats:italic>\n                    \/\n                    <jats:italic>AR<\/jats:italic>\n                    \/DHT signaling, and endorsing pro-apoptotic over anti-apoptotic pathways.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-47374-0","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:55:18Z","timestamp":1775537718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Myricetin alleviates testosterone-induced benign prostatic hyperplasia by attenuating inflammation, oxidative stress, apoptosis and androgen signaling"],"prefix":"10.1038","volume":"16","author":[{"given":"Ghada","family":"Alomari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa","family":"Al-Trad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janti","family":"Qar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Tahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Abu Haija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"Al-najjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Albokhadaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Shousha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed O.","family":"Alameen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Shukry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"47374_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26175377","author":"MC Dias","year":"2021","unstructured":"Dias, M. C., Pinto, D. & Silva, A. M. S. Plant flavonoids: Chemical characteristics and biological activity. Molecules https:\/\/doi.org\/10.3390\/molecules26175377 (2021).","journal-title":"Molecules"},{"key":"47374_CR2","doi-asserted-by":"publisher","first-page":"1175660","DOI":"10.3389\/fnut.2023.1175660","volume":"10","author":"N Niisato","year":"2023","unstructured":"Niisato, N. & Marunaka, Y. Therapeutic potential of multifunctional myricetin for treatment of type 2 diabetes mellitus. Front. Nutr. 10, 1175660 (2023).","journal-title":"Front. Nutr."},{"key":"47374_CR3","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1021\/acsomega.1c06475","volume":"7","author":"A Arafah","year":"2022","unstructured":"Arafah, A. et al. Myricetin (3,3\u2032,4\u2032,5,5\u2032,7-Hexahydroxyflavone) prevents 5-fluorouracil-induced cardiotoxicity. ACS Omega 7, 4514\u20134524 (2022).","journal-title":"ACS Omega"},{"key":"47374_CR4","doi-asserted-by":"publisher","first-page":"5854","DOI":"10.1002\/fsn3.2513","volume":"9","author":"M Imran","year":"2021","unstructured":"Imran, M. et al. Myricetin: A comprehensive review on its biological potentials. Food Sci. Nutr. 9, 5854\u20135868 (2021).","journal-title":"Food Sci. Nutr."},{"key":"47374_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111017","volume":"134","author":"X Song","year":"2021","unstructured":"Song, X. et al. Myricetin: A review of the most recent research. Biomed. Pharmacother. 134, 111017 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"47374_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109641","author":"W-L Sun","year":"2021","unstructured":"Sun, W.-L. et al. Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2021.109641 (2021).","journal-title":"Cell Rep."},{"key":"47374_CR7","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1002\/ar.24222","volume":"302","author":"Z Zhou","year":"2019","unstructured":"Zhou, Z., Mao, W., Li, Y., Qi, C. & He, Y. Myricetin inhibits breast tumor growth and angiogenesis by regulating VEGF\/VEGFR2 and p38MAPK signaling pathways. Anat. Rec. 302, 2186\u20132192 (2019).","journal-title":"Anat. Rec."},{"key":"47374_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-025-01715-9","volume":"25","author":"H Wei","year":"2025","unstructured":"Wei, H. et al. Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035. BMC Urol. 25, 34 (2025).","journal-title":"BMC Urol."},{"key":"47374_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13020053","author":"A Kaltsas","year":"2025","unstructured":"Kaltsas, A., Giannakas, T., Stavropoulos, M., Kratiras, Z. & Chrisofos, M. Oxidative stress in benign prostatic hyperplasia: Mechanisms, clinical relevance and therapeutic perspectives. Diseases https:\/\/doi.org\/10.3390\/diseases13020053 (2025).","journal-title":"Diseases"},{"key":"47374_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237141","volume":"26","author":"E Csik\u00f3s","year":"2021","unstructured":"Csik\u00f3s, E. et al. Treatment of benign prostatic hyperplasia by natural drugs. Molecules 26, 7141 (2021).","journal-title":"Molecules"},{"key":"47374_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249567","volume":"21","author":"B-R Jin","year":"2020","unstructured":"Jin, B.-R. et al. Anti-proliferative effects of standardized Cornus officinalis on benign prostatic epithelial cells via the PCNA\/E2F1-dependent cell cycle pathway. Int. J. Mol. Sci. 21, 9567 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"47374_CR12","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.75657","volume":"43","author":"N Dhingra","year":"2011","unstructured":"Dhingra, N. & Bhagwat, D. Benign prostatic hyperplasia: An overview of existing treatment. Indian J. Pharmacol. 43, 6 (2011).","journal-title":"Indian J. Pharmacol."},{"key":"47374_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.prnil.2023.11.004","volume":"12","author":"A Halawani","year":"2024","unstructured":"Halawani, A. et al. Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate Int. 12, 57\u201364 (2024).","journal-title":"Prostate Int."},{"key":"47374_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00812-3","volume":"29","author":"J-S Liu","year":"2022","unstructured":"Liu, J.-S. et al. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer. J. Biomed. Sci. 29, 29 (2022).","journal-title":"J. Biomed. Sci."},{"key":"47374_CR15","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1159\/000492009","volume":"48","author":"C Ye","year":"2018","unstructured":"Ye, C. et al. The natural compound myricetin effectively represses the malignant progression of prostate cancer by inhibiting PIM1 and disrupting the PIM1\/CXCR4 interaction. Cell. Physiol. Biochem. 48, 1230\u20131244 (2018).","journal-title":"Cell. Physiol. Biochem."},{"key":"47374_CR16","doi-asserted-by":"publisher","DOI":"10.21315\/mjms2017.24.5.11","volume":"24","author":"WN Arifin","year":"2017","unstructured":"Arifin, W. N. & Zahiruddin, W. M. Sample size calculation in animal studies using resource equation approach. Malays. J. Med. Sci. 24, 101 (2017).","journal-title":"Malays. J. Med. Sci."},{"key":"47374_CR17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s11033-025-10847-y","volume":"52","author":"G Alomari","year":"2025","unstructured":"Alomari, G., Al-Trad, B., Al-Najjar, A. & Haija, Y. A. Stigmasterol as a ptotential phytotherapeutic agent for benign prostatic hyperplasia: modulation of inflammation, oxidative stress, and apoptosis. Mol. Biol. Rep. 52, 740 (2025).","journal-title":"Mol. Biol. Rep."},{"key":"47374_CR18","doi-asserted-by":"publisher","first-page":"096032712110668","DOI":"10.1177\/09603271211066843","volume":"41","author":"SB Ahmad","year":"2022","unstructured":"Ahmad, S. B. et al. Myricetin (3, 3\u2032, 4\u2032, 5, 5\u2032, 7-hexahydroxyflavone) prevents ethanol-induced biochemical and inflammatory damage in the liver of Wistar rats. Hum. Exp. Toxicol. 41, 09603271211066843 (2022).","journal-title":"Hum. Exp. Toxicol."},{"key":"47374_CR19","doi-asserted-by":"crossref","unstructured":"Hassan, F. A. & Al-Shawi, N. N. Antioxidant and anti-inflammatory effects of myricetin on 5-fluorouracil-induced hepatotoxicity in male rats (2024).","DOI":"10.21203\/rs.3.rs-4547621\/v1"},{"key":"47374_CR20","doi-asserted-by":"crossref","unstructured":"Buege, J. A. & Aust, S. D. Microsomal lipid peroxidation. In Methods in enzymology 302\u2013310 (Elsevier, 1978).","DOI":"10.1016\/S0076-6879(78)52032-6"},{"key":"47374_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"47374_CR22","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/iju.15518","volume":"31","author":"S Inamura","year":"2024","unstructured":"Inamura, S. & Terada, N. Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options. Int. J. Urol. 31, 968\u2013974 (2024).","journal-title":"Int. J. Urol."},{"key":"47374_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41419-025-07783-x","volume":"16","author":"J Li","year":"2025","unstructured":"Li, J. et al. TNF-\u03b1 modulates cell proliferation via SOX4\/TGF-\u03b2\/Smad signaling in benign prostatic hyperplasia. Cell Death Dis. 16, 472 (2025).","journal-title":"Cell Death Dis."},{"key":"47374_CR24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/jcm12051821","volume":"12","author":"X Naiyila","year":"2023","unstructured":"Naiyila, X. et al. A novel insight into the immune-related interaction of inflammatory cytokines in benign prostatic hyperplasia. J. Clin. Med. 12, 1821 (2023).","journal-title":"J. Clin. Med."},{"key":"47374_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/MOU.0b013e32835abd4a","volume":"23","author":"Y Bostanci","year":"2013","unstructured":"Bostanci, Y., Kazzazi, A., Momtahen, S., Laze, J. & Djavan, B. Correlation between benign prostatic hyperplasia and inflammation. Curr. Opin. Urol. 23, 5\u201310 (2013).","journal-title":"Curr. Opin. Urol."},{"key":"47374_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12012-016-9382-y","volume":"17","author":"Y Qiu","year":"2017","unstructured":"Qiu, Y., Cong, N., Liang, M., Wang, Y. & Wang, J. Systems pharmacology dissection of the protective effect of myricetin against acute ischemia\/reperfusion-induced myocardial injury in isolated rat heart. Cardiovasc. Toxicol. 17, 277\u2013286 (2017).","journal-title":"Cardiovasc. Toxicol."},{"key":"47374_CR27","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1007\/s11033-021-06637-x","volume":"48","author":"M Berk\u00f6z","year":"2021","unstructured":"Berk\u00f6z, M. et al. Prophylactic effect of myricetin and apigenin against lipopolysaccharide-induced acute liver injury. Mol. Biol. Rep. 48, 6363\u20136373 (2021).","journal-title":"Mol. Biol. Rep."},{"key":"47374_CR28","first-page":"139","volume":"2019","author":"AF Cicero","year":"2019","unstructured":"Cicero, A. F. et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch. Ital. Urol. Androl. 2019, 139\u2013152 (2019).","journal-title":"Arch. Ital. Urol. Androl."},{"key":"47374_CR29","doi-asserted-by":"publisher","first-page":"719081","DOI":"10.3389\/fphar.2021.719081","volume":"12","author":"A Salimi","year":"2021","unstructured":"Salimi, A., Jamali, Z. & Shabani, M. Antioxidant potential and inhibition of mitochondrial permeability transition pore by myricetin reduces aluminium phosphide-induced cytotoxicity and mitochondrial impairments. Front. Pharmacol. 12, 719081 (2021).","journal-title":"Front. Pharmacol."},{"key":"47374_CR30","first-page":"87","volume":"5","author":"A Barzegar","year":"2016","unstructured":"Barzegar, A. Antioxidant activity of polyphenolic myricetin in vitro cell- free and cell-based systems. Mol. Biol. Res. Commun. 5, 87\u201395 (2016).","journal-title":"Mol. Biol. Res. Commun."},{"key":"47374_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/09603271211066843","volume":"41","author":"SB Ahmad","year":"2022","unstructured":"Ahmad, S. B. et al. Myricetin (3,3\u2032,4\u2032,5,5\u2032,7-hexahydroxyflavone) prevents ethanol-induced biochemical and inflammatory damage in the liver of Wistar rats. Hum. Exp. Toxicol. 41, 1\u201310 (2022).","journal-title":"Hum. Exp. Toxicol."},{"key":"47374_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1080\/13880209.2016.1275704","volume":"55","author":"SM Hassan","year":"2017","unstructured":"Hassan, S. M., Khalaf, M. M., Sadek, S. A. & Abo-Youssef, A. M. Protective effects of apigenin and myricetin against cisplatin-induced nephrotoxicity in mice. Pharm. Biol. 55, 766\u2013774 (2017).","journal-title":"Pharm. Biol."},{"key":"47374_CR33","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.4314\/tjpr.v16i11.3","volume":"16","author":"M Mao","year":"2017","unstructured":"Mao, M. & Huang, M. Myricetin attenuates lung inflammation and provides protection against lipopolysaccharide-induced acute lung injury by inhibition of NF-\u03baB pathway in rats. Trop. J. Pharm. Res. 16, 2585\u20132593 (2017).","journal-title":"Trop. J. Pharm. Res."},{"key":"47374_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.biopha.2016.05.019","volume":"82","author":"R Bertin","year":"2016","unstructured":"Bertin, R. et al. Activity of myricetin and other plant-derived polyhydroxyl compounds in human LDL and human vascular endothelial cells against oxidative stress. Biomed. Pharmacother. 82, 472\u2013478 (2016).","journal-title":"Biomed. Pharmacother."},{"key":"47374_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116963","volume":"177","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Myricetin ameliorates cognitive impairment in 3\u00d7Tg Alzheimer\u2019s disease mice by regulating oxidative stress and tau hyperphosphorylation. Biomed. Pharmacother. 177, 116963 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"47374_CR36","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1080\/14786419.2022.2089138","volume":"37","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. The protective effects of myricetin against acute liver failure via inhibiting inflammation and regulating oxidative stress via Nrf2 signaling. Nat. Prod. Res. 37, 798\u2013802 (2023).","journal-title":"Nat. Prod. Res."},{"key":"47374_CR37","doi-asserted-by":"publisher","DOI":"10.4149\/gpb_2025002","author":"M Zhang","year":"2025","unstructured":"Zhang, M., Song, X. & Zhan, M. Myricetin protects airway epithelial cells against cigarette smoke extract-induced inflammation and oxidative stress by suppressing autophagy. Gen. Physiol. Biophys. https:\/\/doi.org\/10.4149\/gpb_2025002 (2025).","journal-title":"Gen. Physiol. Biophys."},{"key":"47374_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ajur.2017.11.005","volume":"5","author":"EH Kim","year":"2018","unstructured":"Kim, E. H., Brockman, J. A. & Andriole, G. L. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J. Urol. 5, 28\u201332 (2018).","journal-title":"Asian J. Urol."},{"key":"47374_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/13685538.2024.2391380","volume":"27","author":"H Wang","year":"2024","unstructured":"Wang, H., Liu, C., Dong, Z., Chen, X. & Zhang, P. Prostate-specific antigen, androgen, progesterone and oestrogen receptors in benign prostatic hyperplasia: Human tissues and animal model study. Aging Male 27, 2391380 (2024).","journal-title":"Aging Male"},{"key":"47374_CR40","volume":"9","author":"T Boam","year":"2015","unstructured":"Boam, T. Anti-androgenic effects of flavonols in prostate cancer. Ecancermedicalscience 9, 585 (2015).","journal-title":"Ecancermedicalscience"},{"key":"47374_CR41","doi-asserted-by":"publisher","first-page":"15655","DOI":"10.1007\/s11356-022-23033-5","volume":"30","author":"CN Ikeji","year":"2023","unstructured":"Ikeji, C. N., Adedara, I. A. & Farombi, E. O. Dietary myricetin assuages atrazine-mediated hypothalamic-pituitary-testicular axis dysfunction in rats. Environ. Sci. Pollut. Res. Int. 30, 15655\u201315670 (2023).","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"47374_CR42","doi-asserted-by":"publisher","first-page":"11327","DOI":"10.1080\/10408398.2022.2090893","volume":"63","author":"X Hu","year":"2023","unstructured":"Hu, X. et al. The consequence and mechanism of dietary flavonoids on androgen profiles and disorders amelioration. Crit. Rev. Food Sci. Nutr. 63, 11327\u201311350 (2023).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"47374_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293682","volume":"18","author":"RA Rasheed","year":"2023","unstructured":"Rasheed, R. A. et al. Diacerein provokes apoptosis, improves redox balance, and downregulates PCNA and TNF-\u03b1 in a rat model of testosterone-induced benign prostatic hyperplasia: A new non-invasive approach. PLoS ONE 18, e0293682 (2023).","journal-title":"PLoS ONE"},{"key":"47374_CR44","doi-asserted-by":"publisher","first-page":"60446","DOI":"10.18632\/oncotarget.11108","volume":"7","author":"Y Li","year":"2016","unstructured":"Li, Y. et al. Chemoprevention of intestinal tumorigenesis by the natural dietary flavonoid myricetin in APCMin\/+ mice. Oncotarget 7, 60446\u201360460 (2016).","journal-title":"Oncotarget"},{"key":"47374_CR45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3892\/or.2016.4777","volume":"36","author":"D Jiao","year":"2016","unstructured":"Jiao, D. & Zhang, X. D. Myricetin suppresses p21-activated kinase 1 in human breast cancer MCF-7 cells through downstream signaling of the \u03b2-catenin pathway. Oncol. Rep. 36, 342\u2013348 (2016).","journal-title":"Oncol. Rep."},{"key":"47374_CR46","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2022.5110","volume":"49","author":"S-H Han","year":"2022","unstructured":"Han, S.-H. et al. Myricetin induces apoptosis through the MAPK pathway and regulates JNK\u2011mediated autophagy in SK\u2011BR\u20113 cells. Int. J. Mol. Med. 49, 54 (2022).","journal-title":"Int. J. Mol. Med."},{"key":"47374_CR47","first-page":"1285","volume":"11","author":"SA Ayatollahi","year":"2012","unstructured":"Ayatollahi, S. A. et al. BCL-2 and Bax expression in skin flaps treated with Finasteride or Azelaic Acid. Iran. J. Pharm. Res. 11, 1285\u20131290 (2012).","journal-title":"Iran. J. Pharm. Res."},{"key":"47374_CR48","first-page":"919","volume":"32","author":"JM Golbano","year":"2008","unstructured":"Golbano, J. M., L\u00f3ppez-Aparicio, P., Recio, M. N. & P\u00e9rez-Albarsanz, M. A. Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int. J. Oncol. 32, 919\u2013924 (2008).","journal-title":"Int. J. Oncol."},{"key":"47374_CR49","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/molehr\/4.12.1099","volume":"4","author":"A Basu","year":"1998","unstructured":"Basu, A. & Haldar, S. The relationship between BcI2, Bax and p53: Consequences for cell cycle progression and cell death. Mol. Hum. Reprod. 4, 1099\u20131109 (1998).","journal-title":"Mol. Hum. Reprod."},{"key":"47374_CR50","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2174\/1871520613666131125123059","volume":"13","author":"X-H Zhang","year":"2013","unstructured":"Zhang, X.-H. et al. Myricetin induces apoptosis in HepG2 cells through Akt\/p70S6K\/bad signaling and mitochondrial apoptotic pathway. Anti-Cancer Agents Med. Chem. 13, 1575\u20131581 (2013).","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"47374_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1515\/reveh-2020-0051","volume":"36","author":"A Shah","year":"2021","unstructured":"Shah, A., Shah, A. A., N, K. & Lobo, R. Mechanistic targets for BPH and prostate cancer\u2013A review. Rev. Environ. Health 36, 261\u2013270 (2021).","journal-title":"Rev. Environ. Health"},{"key":"47374_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.59298\/IDOSRJAS\/2025\/101.263500","volume":"10","author":"EK Mugisha","year":"2025","unstructured":"Mugisha, E. K. Pathophysiology of benign prostatic hyperplasia: Cellular and molecular mechanisms. IDOSR J. Appl. Sci. 10, 26\u201335 (2025).","journal-title":"IDOSR J. Appl. Sci."},{"key":"47374_CR53","first-page":"160","volume":"4","author":"W Santosh","year":"2014","unstructured":"Santosh, W. Anti-angiogenic activity of natural flavonoid myricetin on chick chorioallantoic membrane (CAM) in-vivo. Int. J. Pharm. 4, 160\u2013165 (2014).","journal-title":"Int. J. Pharm."},{"key":"47374_CR54","unstructured":"Salisbury, B., Leslie, S. & Tadi, P. 5\u03b1-reductase inhibitors. StatPearls (2024)."},{"key":"47374_CR55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.21037\/tau-22-690","volume":"12","author":"B Chislett","year":"2023","unstructured":"Chislett, B. et al. 5-alpha reductase inhibitors use in prostatic disease and beyond. Transl. Androl. Urol. 12, 487\u2013496 (2023).","journal-title":"Transl. Androl. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47374-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47374-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47374-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:05:42Z","timestamp":1775649942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47374-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47374"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47374-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11651"}}